Barbara A. Parker, M.D.
Professor of Clinical Medicine
Division of Hematology-Oncology
Medical Director, Oncology Services
Moores UCSD Cancer Center
Division of Hematology/Oncology
University of California, San Diego
Moores Cancer Center
3855 Health Sciences Drive, MC-0987
La Jolla, CA 92093
Office: (858) 822-6135
FAX: (858) 822-6136
|B.A. - Chemstry||University of North Carolina at Chapel Hill, NC||1974|
|M.D. - Medicine||Stanford University of Medicine, CA||1981|
|Intern/Resident - Medicine||UC San Diego Department of Medicine, CA||1982-1984|
Chief Resident - Medicine
|UC San Diego Department of Medicine, CA||1985|
|Fellowship - Hematology/Oncology||UC San Diego Department of Medicine, CA||1987|
My research interests include personalized approaches to cancer screening and prevention, new therapies on genomic profiling and breast cancer survivorship issues. I served as the Medical Director of the WHEL Diet Study. I currently serve as the CALGB/Alliance/ACTION clinical trials UCSD Principal Investigator and serve on the CALGB/Alliance Breast Committee and the CALGB/Alliance Prevention Committee. I serve as site PI and Co-Chair of the Diagnosis and Treatment Clinical Care and Research Group of the California Athena Breast Health Network, co-investigator of studies of life-style modification in breast cancer survivors, and co-investigator of studies involving new agents. My clinical practice is comprised of breast cancer patients.
Al-Delaimy WK, Flatt SW, Natarajan L, Laughlin GA, Rock CL, Gold EB, Caan BJ, Parker BA, Pierce JPP. IGF-1 and energy-related factors and risk of additional breast cancer in the WHEL study. Endocr Relat Cancer. 2011 Mar 3;18(2):235-44
Saquib N, Pierce JP, Saquib J, Flatt SW, Natarajan L, Bardwell WA, Patterson RE, Stefanick ML, Thomson CA, Rock CL, Jones LA, Gold EB, Karanja N, Parker BA. Poor physical health predicts time to additional breast cancer events and mortality in breast cancer survivors. Psychooncology. 2011 Mar; 20(3):252-9.
Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, Parker BA, Wu AHB, Pierce JP. Tamoxifen Metabolite Concentrations, CYP2D6 Genotype and Breast Cancer Outcomes. Clinical Pharmacology & Therapeutics 2011 Mar 23 NIHMSID: 269160
Caan B, Natarajan L, Parker BA, Gold EB, Thomson CA, Newman V, Rock CL, Pu M, Al-Delaimy WK, Pierce JP. Soy Food Consumption and Breast Cancer Prognosis. Cancer Epidemiol Biomarkers Prev. 2011 May; 20:854-858
Patterson RE, Saquib N, Natarajan L, Rock CL, Parker BA, Thomson CA, Pierce JP. Improvement in self-reported physical health predicts longer survival among women with a history of breast cancer. Breast Cancer Res Treat. 2011 Jun; 127(2):541-7.
Ancoli-Israel S, Rissling M, Neikrug A, Trofimenko V, Natarajan L, Parker BA, Lawton S, Desan P, Liu L. Light treatment prevents fatigue in women undergoing chemotherapy for breast cancer. Support Care Cancer. 2011 Jun 11.
Liu L, Rissling M, Natarajan L, Fiorentino L, Mills PJ, Dimsdale JE, Sadler GR, Parker BA, Ancoli-Israel S. The longitudinal relationship between fatigue and sleep in breast cancer patients undergoing chemotherapy. Sleep. 2012 Feb 1; 35(2):237-45.
Liu L, Mills PJ, Rissling M, Fiorentino L, Natarajan L, Dimsdale JE, Sadler, GR, Parker BA, Ancoli-Israel S. Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy. Brain Behav Immun. 2012 Mar 2. [Epub ahead of print]
Yost SE, Smith EN, Schwab RB, Bao L, Jung H, Wang X, Voest E, Pierce JP, Messer K, Parker BA, Harismendy O, Frazer KA. Identification of high-confidence somatic mutations in whole genome sequence of formalin-fixed breast cancer specimens. Nucleic Acids Res. 2012 Apr 6. [Epub ahead of print]
Jeste N, Liu L, Rissling M, Trofimenko V, Natarajan L, Parker BA, Ancoli-Israel S. Prevention of quality-of-life deterioration with light therapy is associated with changes in fatigue in women with breast cancer undergoing chemotherapy. Qual Life Res. 2012 Aug 3. [Epub ahead of print] PubMed PMID: 22865153.